In the US, adalimumab is indicated for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult crohn’s disease, pediatric crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis.

In the EU it is indicated for the treatment of:

• plaque psoriasis (a disease causing red, scaly patches on the skin);
• psoriatic arthritis (a disease causing red, scaly patches on the skin with inflammation of the joints);
• rheumatoid arthritis (a disease causing inflammation of the joints);
• axial spondyloarthritis (inflammation of the spine causing back pain), including ankylosing spondylitis and when X-ray does not show disease but there are clear signs of inflammation;
• polyarticular juvenile idiopathic arthritis and active enthesitis-related arthritis (both rare diseases causing inflammation in the joints);
• Crohn’s disease (a disease causing inflammation of the gut);
• ulcerative colitis (a disease causing inflammation and ulcers in the lining of the gut);
• hidradenitis suppurativa (acne inversa), a long-term skin disease that causes lumps, abscesses (collections of pus) and scarring on the skin;
• non-infectious uveitis (inflammation of the layer beneath the white of the eyeball).
• chronic cases of aggressive progressive pulmonary and bone sarcoidosis.